Start here if you're new
what it is
Fractyl Health is trying to treat diabetes and obesity with a gut device and 2 gene-therapy programs.
how it gets paid
Last year Fractyl Health made $93K in revenue.
what just happened
Quarterly revenue was $90K, and EPS was -$1.79.
At a glance
n/a balance sheet
-$1.62 fy2024 eps est
$2M fy2026 rev est
n/m operating margin — pre-revenue
~$71M market cap
xvary composite: 18/100 — weak
What they do
Fractyl Health is trying to treat diabetes and obesity with a gut device and 2 gene-therapy programs.
Fractyl's moat is clinical optionality, not scale. It has $93K of annual revenue against $57M of long-term debt, so the company looks more like a laboratory than a business. If Revita or Rejuva works, you own 2 shots on goal. If they do not, you own a tiny revenue base and a very large financing bill.
How they make money
$93K
annual revenue
total revenue
$93K
n/a
The products that matter
late-stage metabolic procedure
Revita
Phase 3 · readout expected Q4 2026
this is the asset carrying almost all of the equity story, with pivotal data expected in Q4 2026 and no meaningful product revenue yet.
the main bet
preclinical gene therapy
Rejuva
preclinical stage
it adds optionality, but near-term commercial contribution is effectively $0 and it does not reduce the Revita dependency.
long-dated option
Key numbers
$93K
annual revenue
That is the whole business for a year, and it is smaller than many homes.
$57M
debt load
Debt is 612x revenue, so financing risk is doing the heavy lifting here.
44.4%
gross margin (Q)
The product can gross profit, but only on a $90K quarterly base.
1.6
beta
The stock moves about 60% more than the market, so your nerves matter.
Financial health
n/a
strength
- balance sheet grade n/a
- risk rank 5 — safer than 5% of stocks
- price stability 5 / 100
- long-term debt $57M (44% of capital)
n/a — functional but not a standout on the balance sheet.
Total return vs. market
Return history isn't available for GUTS right now.
source: institutional data · return history unavailable
What just happened
missed estimates
Quarterly revenue was $90K, and EPS was -$1.79.
vs. prior year revenue growth looks huge from a tiny base—it is still rounding error in dollars. Gross margin was 44.4% on negligible sales, so do not over-read the percentage.
$90K
revenue (Q)
-$1.79
eps (Q)
44.4%
gross margin (Q)
the number that mattered
$90K of quarterly revenue matters because it shows the company is still pre-scale—headline vs. prior year growth is noise on a tiny base.
source: EDGAR quarterly filing, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is Revita Phase 3 failure or delay. This page has $93K of revenue, $57M of long-term debt, and one late-stage asset carrying almost the entire equity story.
med
Revita Phase 3 fails
Revita is the lead asset and the readout is expected in Q4 2026. If the data miss, the company loses the only near-term proof point supporting a ~$71M market cap.
impact: it hits the asset behind nearly all of the current equity narrative.
med
cash burn meets a hard balance sheet
With $93K of revenue and $57M of long-term debt, Fractyl does not have a self-funding business. Trial costs and corporate overhead still need cash before any commercial proof exists.
impact: new capital could dilute you or arrive on worse terms if the timeline stretches.
med
single-asset dependence
Rejuva is preclinical. That means there is no late-stage backup if Revita disappoints and no diversified revenue stream to cushion the stock.
impact: one program setback can rewrite the valuation, not just trim the upside.
one late-stage readout is carrying a ~$71M market cap while $57M of long-term debt leaves management less room to miss on timing, spending, or data.
source: institutional data · regulatory filings · risk analysis
Pay attention to
catalyst
Revita Phase 3 top-line data
The key readout is expected in Q4 2026. If you track one date, track the one that can prove or break the whole Revita thesis.
balance sheet
debt versus runway
$57M of long-term debt already matters. Any sign that financing needs are growing faster than expected would move this story from clinical risk to capital-structure risk.
execution
expense discipline after the EPS miss
Q3 2025 EPS missed badly at -$0.71 versus -$0.33 expected. The next few updates need to show spending is at least tracking plan.
management
new CFO capital decisions
Lara Smith Weber joined in January 2026. In a company this small, financing choices can matter as much as product updates.
Analyst rankings
risk profile
high risk
risk rank 5 — significant risk of large drawdowns.
chart momentum
below average
momentum rank 4 — analysts see underperformance risk in the near term.
source: institutional data
Institutional activity
institutional ownership data for GUTS is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$2
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive